TScan Therapeutics annual depreciation and amortization
2020
2021
2022
2023
2024
2025
TScan Therapeutics Depreciation & Amortization Growth & History (TCRX)
TScan Therapeutics's depreciation and amortization was $2.9M for fiscal 2025.
View full TScan Therapeutics company overviewTScan Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.9M | −$1.2M | −29.27% |
| 2024 | 2024-12-31 | $4.1M | −$1.3M | −24.07% |
| 2023 | 2023-12-31 | $5.4M | $300,000 | +5.88% |
| 2022 | 2022-12-31 | $5.1M | $1.8M | +54.55% |
| 2021 | 2021-12-31 | $3.3M | $2.1M | +175.00% |
| 2020 | 2020-12-31 | $1.2M | — | — |
TScan Therapeutics quarterly depreciation and amortization
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $699,000 | $1,000 | +0.14% |
| Q1 2026 | 2026-03-31 | $693,000 | $15,000 | +2.21% |
| Q4 2025 | 2025-12-31 | $723,000 | — | — |
| Q3 2025 | 2025-09-30 | $767,000 | −$260,000 | −25.32% |
| Q2 2025 | 2025-06-30 | $698,000 | −$418,000 | −37.46% |
| Q1 2025 | 2025-03-31 | $678,000 | −$576,000 | −45.93% |
| Q3 2024 | 2024-09-30 | $1.0M | −$259,000 | −20.14% |
| Q2 2024 | 2024-06-30 | $1.1M | −$180,000 | −13.89% |
| Q1 2024 | 2024-03-31 | $1.3M | −$245,000 | −16.34% |
| Q3 2023 | 2023-09-30 | $1.3M | $35,000 | +2.80% |
| Q2 2023 | 2023-06-30 | $1.3M | $89,000 | +7.37% |
| Q1 2023 | 2023-03-31 | $1.5M | $304,000 | +25.44% |
| Q3 2022 | 2022-09-30 | $1.3M | $195,000 | +18.47% |
| Q2 2022 | 2022-06-30 | $1.2M | $546,000 | +82.60% |
| Q1 2022 | 2022-03-31 | $1.2M | $726,000 | +154.80% |
| Q3 2021 | 2021-09-30 | $1.1M | $710,000 | +205.20% |
| Q2 2021 | 2021-06-30 | $661,000 | — | — |
| Q1 2021 | 2021-03-31 | $469,000 | — | — |
| Q3 2020 | 2020-09-30 | $346,000 | — | — |
TScan Therapeutics depreciation and amortization trends
Over the last five fiscal years, TScan Therapeutics's depreciation and amortization increased from $1.2M to $2.9M, a change of $1.7M. The latest reported quarter, Q2 2026, shows $699,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TScan Therapeutics source filings ↗